US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
WO1992019266A1
(en)
|
1991-05-06 |
1992-11-12 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
EP0752248B1
(en)
|
1992-11-13 |
2000-09-27 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
WO1996009380A1
(en)
|
1994-09-23 |
1996-03-28 |
The University Of British Columbia |
Method of enhancing expression of mhc class i molecules bearing endogenous peptides
|
DE69519521T2
(de)
|
1994-10-03 |
2001-06-28 |
Us Gov Nat Inst Health |
Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
US5780426A
(en)
|
1995-06-07 |
1998-07-14 |
Ixsys, Incorporated |
Fivemer cyclic peptide inhibitors of diseases involving αv β3
|
US5767071A
(en)
|
1995-06-07 |
1998-06-16 |
Ixsys Incorporated |
Sevenmer cyclic peptide inhibitors of diseases involving αv β3
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
JPH11514853A
(ja)
|
1995-09-08 |
1999-12-21 |
ジエンザイム コーポレイション |
遺伝子治療のための改良されたaavベクター
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
ES2246069T3
(es)
|
1997-05-02 |
2006-02-01 |
Genentech, Inc. |
Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
US6635472B1
(en)
|
1997-08-15 |
2003-10-21 |
Rubicon Laboratory, Inc. |
Retrovirus and viral vectors
|
EP1015619A1
(en)
|
1997-09-19 |
2000-07-05 |
The Trustees Of The University Of Pennsylvania |
Methods and cell line useful for production of recombinant adeno-associated viruses
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
EP1068241B1
(en)
|
1998-04-02 |
2007-10-10 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
BR9912671A
(pt)
|
1998-08-07 |
2001-05-02 |
Univ Washington |
Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
|
US6491907B1
(en)
|
1998-11-10 |
2002-12-10 |
The University Of North Carolina At Chapel Hill |
Recombinant parvovirus vectors and method of making
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
US6365619B1
(en)
|
1999-07-22 |
2002-04-02 |
Novartis Ag |
Treatment of arteriosclerosis
|
ES2308989T3
(es)
|
1999-08-09 |
2008-12-16 |
Targeted Genetics Corporation |
Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
|
US6521749B1
(en)
|
1999-09-21 |
2003-02-18 |
Genetics Institute, Inc. |
GL50 nucleic acids and uses therefor
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
US6723316B2
(en)
|
1999-12-22 |
2004-04-20 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
|
US7223593B2
(en)
|
2000-01-21 |
2007-05-29 |
Biovex Limited |
Herpes virus strains for gene therapy
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
WO2002000717A2
(en)
|
2000-06-23 |
2002-01-03 |
Maxygen, Inc. |
Novel co-stimulatory molecules
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
TR201807700T4
(tr)
|
2000-07-03 |
2018-06-21 |
Squibb Bristol Myers Co |
Çözünür CTLA4 mutant moleküllerinin kullanımları.
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
NZ527687A
(en)
|
2001-05-11 |
2005-10-28 |
Wellstat Biolog Corp Formerly |
Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
|
AU2002368044A1
(en)
|
2001-06-22 |
2004-04-19 |
Maxygen, Inc. |
Co-stimulatory molecules
|
JP2004537305A
(ja)
|
2001-07-11 |
2004-12-16 |
ユニバーシティー オブ マイアミ |
腫瘍細胞の処置のための組換えvsv
|
CN1304559C
(zh)
|
2001-10-09 |
2007-03-14 |
杭州康科生物技术有限公司 |
表达热休克蛋白的溶瘤微生物及其应用
|
EP1461073B1
(en)
|
2001-11-30 |
2010-01-06 |
The Government of the United States of America, as represented by the Secretary Department of Health and Human Services |
Peptide agonists of prostate-specific antigen, and uses therefor
|
US7235631B2
(en)
|
2002-02-07 |
2007-06-26 |
Mayo Foundation For Medical Education And Research |
ICOS mutants
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
CA2479763A1
(en)
|
2002-03-27 |
2003-10-09 |
Baylor College Of Medicine |
Potent oncolytic herpes simplex virus for cancer therapy
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
CA2489523A1
(en)
|
2002-06-21 |
2003-12-31 |
Wellstat Biologics Corporation |
Administration of therapeutic viruses
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
US20050260601A1
(en)
|
2002-09-09 |
2005-11-24 |
Whitt Michael A |
Recombinant mutants of rhabdovirus and methods of use thereof
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
BRPI0316779B1
(pt)
|
2002-12-16 |
2020-04-28 |
Genentech Inc |
anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
ES2319424T3
(es)
|
2003-03-27 |
2009-05-07 |
Ottawa Health Research Institute |
Virus mutantes de la estomatitis vesivular y sus usos.
|
DE602004018927D1
(de)
|
2003-06-18 |
2009-02-26 |
Genelux Corp |
Modifizierte rekombinante vacciniaviren, verwendungen davon
|
EP2298926A1
(en)
|
2003-09-30 |
2011-03-23 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
WO2005049846A2
(en)
|
2003-11-17 |
2005-06-02 |
Crusade Laboratories Limited |
Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
PT1718677E
(pt)
|
2003-12-19 |
2012-07-18 |
Genentech Inc |
Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
|
PL1737891T3
(pl)
|
2004-04-13 |
2013-08-30 |
Hoffmann La Roche |
Przeciwciała przeciw selektynie p
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
US7731952B2
(en)
|
2004-06-24 |
2010-06-08 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
US8911726B2
(en)
|
2004-09-22 |
2014-12-16 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human Igg4 antibodies
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
EP1819823A2
(en)
|
2004-12-01 |
2007-08-22 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
US20070020238A1
(en)
|
2005-06-01 |
2007-01-25 |
David Baltimore |
Method of targeted gene delivery using viral vectors
|
CA2613310C
(en)
|
2005-06-23 |
2014-06-17 |
Baylor College Of Medicine |
Use of mutant herpes simplex virus-2 for cancer therapy
|
SI1907424T1
(sl)
|
2005-07-01 |
2015-12-31 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
ES2439641T3
(es)
|
2005-12-20 |
2014-01-24 |
Bristol-Myers Squibb Company |
Composiciones y procedimientos de producción de una composición
|
PT2520168E
(pt)
|
2006-07-21 |
2014-04-29 |
California Inst Of Techn |
Administração de gene alvo para vacinação de células dendríticas
|
US8052968B2
(en)
|
2006-10-16 |
2011-11-08 |
Genelux Corporation |
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
|
US20100178684A1
(en)
|
2006-12-21 |
2010-07-15 |
Woo Savio L C |
Transgenic oncolytic viruses and uses thereof
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
EP2114420B1
(en)
|
2007-02-16 |
2016-01-27 |
Virttu Biologics Limited |
Herpes simplex viruses and methods of viral replication
|
EP3357338A1
(en)
|
2007-03-30 |
2018-08-08 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
EP2171071B1
(en)
|
2007-06-15 |
2015-08-05 |
Genelux Corporation |
Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
|
NZ580670A
(en)
|
2007-06-21 |
2011-09-30 |
Univ Muenchen Tech |
Biological active proteins having increased in vivo and/or vitro stability
|
AU2008293885A1
(en)
|
2007-07-13 |
2009-03-05 |
The John Hopkins University |
B7-DC variants
|
JP2010533718A
(ja)
|
2007-07-18 |
2010-10-28 |
ジェネラックス・コーポレイション |
腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
|
PH12018501459A1
(en)
*
|
2007-09-26 |
2019-11-11 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
US20090136917A1
(en)
|
2007-10-25 |
2009-05-28 |
Szalay Aladar A |
Systems and methods for viral therapy
|
EP2612868B1
(en)
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
CN101925612A
(zh)
|
2007-11-27 |
2010-12-22 |
维文蒂阿生物技术公司 |
针对癌相关的nfkbib变体的表位的抗体及其用途
|
LT2222861T
(lt)
|
2007-12-11 |
2018-03-26 |
The University Of North Carolina At Chapel Hill |
Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
EP2300023A2
(en)
|
2008-05-16 |
2011-03-30 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
EP2307033A4
(en)
|
2008-05-29 |
2012-06-13 |
Gen Hospital Corp |
USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
|
EP2398466B1
(en)
|
2008-11-24 |
2021-02-17 |
Massachusetts Institute of Technology |
Methods and compositions for localized nanoparticle delivery to a tumor
|
CN108997498A
(zh)
|
2008-12-09 |
2018-12-14 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
US8481297B2
(en)
|
2009-01-08 |
2013-07-09 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
EP2283810A1
(en)
|
2009-07-16 |
2011-02-16 |
University College Cork-National University of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
US20150359909A1
(en)
|
2009-07-16 |
2015-12-17 |
University College Cork-National University Of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
DK2770061T3
(en)
|
2009-07-24 |
2019-01-07 |
Immune Design Corp |
NON-INTEGRATING LENTIVIRUS VECTORS
|
EP3381937A3
(en)
*
|
2009-08-13 |
2018-10-31 |
The Johns Hopkins University |
Methods of modulating immune function
|
EP3375791A1
(en)
|
2009-09-30 |
2018-09-19 |
Memorial Sloan Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
EP2531216B1
(en)
|
2010-02-04 |
2019-03-27 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
WO2011103584A2
(en)
|
2010-02-19 |
2011-08-25 |
Xencor, Inc. |
Novel ctla4-ig immunoadhesins
|
CN106432474A
(zh)
|
2010-03-12 |
2017-02-22 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
KR20230133410A
(ko)
|
2010-12-09 |
2023-09-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
|
EA201391059A1
(ru)
|
2011-01-18 |
2014-05-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиции для лечения рака и способы их применения
|
EP2686345B1
(en)
|
2011-03-16 |
2018-04-25 |
Amgen Inc. |
Fc variants
|
EA027236B1
(ru)
|
2011-04-08 |
2017-07-31 |
Иммьюн Дизайн Корп. |
Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
CN107519486B
(zh)
|
2011-06-24 |
2021-06-11 |
台北荣民总医院 |
于感染性与恶性疾病的治疗中提升免疫反应的方法
|
HUE040455T2
(hu)
|
2011-06-30 |
2019-03-28 |
Genzyme Corp |
T-sejt aktiválás inhibitorai
|
AU2012277376B2
(en)
|
2011-06-30 |
2016-11-24 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
EP2756521A4
(en)
|
2011-09-16 |
2015-04-22 |
Univ Pennsylvania |
RNA-MANIPULATED T-CELLS FOR THE TREATMENT OF CANCER
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-pd-l1 항체 및 그의 용도
|
SG11201405276PA
(en)
|
2012-02-27 |
2014-10-30 |
Amunix Operating Inc |
Xten conjugate compositions and methods of making same
|
MX362699B
(es)
|
2012-03-30 |
2019-02-01 |
Immune Design Corp |
Partículas de vectores lentivirales teniendo eficiencia de transducción mejorada para células que expresan dc-sign.
|
WO2013156054A1
(en)
*
|
2012-04-16 |
2013-10-24 |
Universität Stuttgart |
The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
|
ES2777778T3
(es)
|
2012-05-11 |
2020-08-06 |
Medimmune Ltd |
Variantes de CTLA-4
|
CA2877986A1
(en)
|
2012-06-27 |
2014-01-03 |
Orban Biotech Llc |
Ctla4 fusion proteins for the treatment of diabetes
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
RS58528B1
(sr)
|
2012-12-03 |
2019-04-30 |
Bristol Myers Squibb Co |
Poboljšanje anti-kancerske aktivnosti imunomodulatornih fc fuzionih proteina
|
BR112015013127A2
(pt)
|
2012-12-04 |
2017-09-26 |
Oncomed Pharm Inc |
imunoterapia com agentes de ligação
|
US9944689B2
(en)
|
2013-03-07 |
2018-04-17 |
The General Hospital Corporation |
Human CTLA4 mutants and use thereof
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
US20160017041A1
(en)
|
2013-03-15 |
2016-01-21 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
WO2014198002A1
(en)
|
2013-06-14 |
2014-12-18 |
Ottawa Hospital Research Institute |
A bacterium producing an interferon binding protein and uses thereof
|
US20160271218A1
(en)
|
2013-06-27 |
2016-09-22 |
Mor Research Applications Ltd. |
Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
CN110511960B
(zh)
|
2013-07-15 |
2023-05-23 |
美国卫生和人力服务部 |
抗人乳头瘤病毒16 e6 t细胞受体
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
EP3835318A1
(en)
|
2014-01-15 |
2021-06-16 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
WO2015113494A1
(zh)
|
2014-01-28 |
2015-08-06 |
北京韩美药品有限公司 |
双功能融合蛋白及其制备方法和用途
|
ES2792849T3
(es)
|
2014-02-10 |
2020-11-12 |
Univ Emory |
Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
|
SG10202008629XA
(en)
|
2014-03-28 |
2020-10-29 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
MX2016013611A
(es)
|
2014-04-25 |
2017-02-02 |
Bristol Myers Squibb Co |
Uso del compuesto antigeno 4 del linfocito t toxico (ctla4) para lograr la remision libre de farmacos en sujetos con artritis reumatoide (ra) temprana.
|
CA2955015A1
(en)
|
2014-07-15 |
2016-01-21 |
Immune Design Corp. |
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
US10555981B2
(en)
|
2014-07-16 |
2020-02-11 |
Transgene S.A. |
Oncolytic virus for expression of immune checkpoint modulators
|
CN107108707A
(zh)
|
2014-08-08 |
2017-08-29 |
小利兰斯坦福大学理事会 |
高亲和力pd‑1药剂以及使用方法
|
SG10201901735XA
(en)
|
2014-09-03 |
2019-03-28 |
Bavarian Nordic As |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
CA2966988A1
(en)
|
2014-11-06 |
2016-05-12 |
Children's Research Institute, Children's National Medical Center |
Immunotherapeutics for cancer and autoimmune diseases
|
EP3020816A1
(en)
|
2014-11-11 |
2016-05-18 |
University College Cork |
Bacterial mediated gene therapy
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
WO2016154684A1
(en)
|
2015-04-02 |
2016-10-06 |
Cancure Limited |
Agents and compositions for eliciting an immune response
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
DK3283508T3
(en)
|
2015-04-17 |
2021-05-31 |
Alpine Immune Sciences Inc |
Immunomodulatory Proteins with Tunable Affinities
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Tigit結合劑和彼之用途
|
IL297090A
(en)
|
2015-07-30 |
2022-12-01 |
Macrogenics Inc |
Molecules that bind pd-1 and methods of using them
|
US20180221503A1
(en)
|
2015-07-31 |
2018-08-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
JP2018534245A
(ja)
*
|
2015-09-14 |
2018-11-22 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法
|
KR20180053752A
(ko)
|
2015-10-02 |
2018-05-23 |
심포젠 에이/에스 |
항-pd-1 항체 및 조성물
|
WO2017181152A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
SG11201808457PA
(en)
*
|
2016-04-15 |
2018-10-30 |
Alpine Immune Sciences Inc |
Icos ligand variant immunomodulatory proteins and uses thereof
|
JP2019522466A
(ja)
|
2016-05-18 |
2019-08-15 |
アルバート アインシュタイン カレッジ オブ メディシン,インコーポレイティド |
変異pd−l1ポリペプチド、t細胞調節多量体ポリペプチド、及びそれらの使用方法
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
EP3872180A1
(en)
|
2016-10-20 |
2021-09-01 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
US20200283500A1
(en)
|
2017-10-18 |
2020-09-10 |
Alpine Immune Sciences, Inc. |
Variant icos ligand immunomodulatory proteins and related compositions and methods
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
CA3136816A1
(en)
|
2019-04-17 |
2020-10-22 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant icos ligand (icosl) fusion proteins
|